Use of tumor caryon single-antibody in physical therapeutic tumor as synergist

Abstract

An application of the tumor cell nucleus monoantibody as the synergist in physically treating solid tumor by directionally combining with the necrotic tissue of tumor specifically and killing the tumor cells by the nuclein carried by it is disclosed. It features that the normal tissue can not be damaged.

Description

technical field [0001] The present invention relates to the technical field of biomedicine, in particular to the new use of tumor cell nuclear monoclonal antibody, and more specifically to the new use of tumor cell nuclear monoclonal antibody as a synergist in physical therapy of various solid tumors. Background technique [0002] (1) Molecular targeted therapy of tumors [0003] 1 Overview [0004] Molecular targeted therapy of tumors is the most dynamic field that has attracted much attention in recent years. It is a tumor-specific treatment in the fundamental sense. Molecular binding. An ideal targeting molecule should have the following characteristics: ① Highly specific target antigen binding; ② Appropriate molecular weight range to facilitate the penetration of the targeting molecule in tumor tissue; ③ High affinity when binding to the target molecule; ④The molecular structure is beneficial for stability and reduces clearance; ⑤Has biological homology with the treat...

AI Technical Summary

Problems solved by technology

[0069] 3) Unsolved problems in radiofrequency ablation

[0111] ② Misembolization and ectopic embolization: Catheters cannot be super-selectively intubated, improper selection of embolic agent, high pressure of injection contrast agent and other reasons may cause embolic agent reflux and misembolization of other organs

And because the vast majority of patients with esophageal cancer are already in the advanced stage when they are diagnosed, not only the local lesions have been extensively infiltrated, but also the distant spread of subclinical lesions or lymph node metastasis have been found. Autopsy found that many cases that were considered to be locally early died at the time of death. More than half of them have distant metastasis, more than 70% have extensive lymph node invasion, and less than 1 / 3 of the cases can be curatively resected. The 5-year survival rate of conventional radiotherapy is only 13%. The main cause of failure accounts for more than 80%. It can be seen that the treatment of esophageal cancer is far from enough by surgery and radiotherapy alone.

However, so far, there has been no report on the new use of tumor cell nuclear monoclonal antibody as a synergist in physical therapy of various solid tumors

Images